BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 8198970)

  • 21. Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias.
    Wojcik I; Szybka M; Golanska E; Rieske P; Blonski JZ; Robak T; Bartkowiak J
    Neoplasma; 2005; 52(4):318-24. PubMed ID: 16059649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma.
    Shibagaki I; Tanaka H; Shimada Y; Wagata T; Ikenaga M; Imamura M; Ishizaki K
    Clin Cancer Res; 1995 Jul; 1(7):769-73. PubMed ID: 9816044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
    Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
    Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53 and MDM2 expression in oral squamous cell carcinoma.
    Matsumura T; Yoshihama Y; Kimura T; Shintani S; Alcalde RE
    Oncology; 1996; 53(4):308-12. PubMed ID: 8692535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple genetic alterations in hamster pancreatic ductal adenocarcinomas.
    Chang KW; Laconi S; Mangold KA; Hubchak S; Scarpelli DG
    Cancer Res; 1995 Jun; 55(12):2560-8. PubMed ID: 7780969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
    Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N
    J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of P53, MDM2 and Ki-67 antigens in soft tissue sarcomas.
    Szadowska A; Olborski B; Harezga-Bal B; Debiec-Rychter M
    Pol J Pathol; 1999; 50(1):9-16. PubMed ID: 10412269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alterations of the p53, Rb and MDM2 genes in osteosarcoma.
    Miller CW; Aslo A; Won A; Tan M; Lampkin B; Koeffler HP
    J Cancer Res Clin Oncol; 1996; 122(9):559-65. PubMed ID: 8781571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Malignant peripheral nerve sheath tumours: high Ki67 labelling index is the significant prognostic indicator.
    Watanabe T; Oda Y; Tamiya S; Kinukawa N; Masuda K; Tsuneyoshi M
    Histopathology; 2001 Aug; 39(2):187-97. PubMed ID: 11493336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P53 mutations in Ewing's sarcoma.
    Park YK; Chi SG; Kim YW; Park HR; Unni KK
    Oncol Rep; 2001; 8(3):533-7. PubMed ID: 11295075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 Mutation and MDM2 amplification in human soft tissue sarcomas.
    Leach FS; Tokino T; Meltzer P; Burrell M; Oliner JD; Smith S; Hill DE; Sidransky D; Kinzler KW; Vogelstein B
    Cancer Res; 1993 May; 53(10 Suppl):2231-4. PubMed ID: 8387391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical and mutational analysis of the p53 tumour suppressor gene and the bcl-2 oncogene in primary testicular germ cell tumours.
    Heidenreich A; Schenkman NS; Sesterhenn IA; Mostofi KF; Moul JW; Srivastava S; Engelmann UH
    APMIS; 1998 Jan; 106(1):90-9; discussion 99-100. PubMed ID: 9524567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.
    Reifenberger G; Liu L; Ichimura K; Schmidt EE; Collins VP
    Cancer Res; 1993 Jun; 53(12):2736-9. PubMed ID: 8504413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 and ras mutations in Ewing's sarcoma.
    Radig K; Schneider-Stock R; Röse I; Mittler U; Oda Y; Roessner A
    Pathol Res Pract; 1998; 194(3):157-62. PubMed ID: 9587933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas.
    Ittmann M; Wieczorek R; Heller P; Dave A; Provet J; Krolewski J
    Am J Pathol; 1994 Aug; 145(2):287-93. PubMed ID: 8053489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer.
    Ko JL; Cheng YW; Chang SL; Su JM; Chen CY; Lee H
    Int J Cancer; 2000 May; 89(3):265-70. PubMed ID: 10861503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.
    Taylor AC; Shu L; Danks MK; Poquette CA; Shetty S; Thayer MJ; Houghton PJ; Harris LC
    Med Pediatr Oncol; 2000 Aug; 35(2):96-103. PubMed ID: 10918230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
    Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
    Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human papillomavirus infection in Egyptian esophageal carcinoma: correlation with p53, p21, mdm2, C-erbB2 and impact on survival.
    Bahnassy AA; Zekri AR; Abdallah S; El-Shehaby AM; Sherif GM
    Pathol Int; 2005 Feb; 55(2):53-62. PubMed ID: 15693850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
    Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
    J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.